ArticleBMC cancer2026
Application of percutaneous cryoablation for pulmonary nodules and influence in pulmonary function.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundCryoablation has been reported as a non-surgical option for early-stage lung cancer and a palliative cytoreductive therapy for advanced disease and pulmonary metastases; however, evidence remains relatively limited. PURPOSE: To evaluate the efficacy and safety of cryoablation in patients with different types of pulmonary nodules and to identify appropriate clinical scenarios for its application.
methodThis retrospective study included 94 patients with 107 pulmonary nodules who underwent CT-guided percutaneous cryoablation between May 2022 and May 2024. Patients were classified into curative-intent (early-stage lung cancer) and palliative-intent (advanced/recurrent lung cancer or pulmonary metastases) groups. The curative group was further subdivided into solitary pulmonary nodules, synchronous multiple primary nodules (sMPN), and second primary lung cancer (SPLC). Primary outcomes were local recurrence-free survival (LRFS) and recurrence-free survival (RFS) in the curative group, and progression-free survival (PFS) in the palliative group. Secondary outcomes included residual nodule progression in sMPN patients, pulmonary function changes and adverse events.
resultSeventy-three patients with 86 nodules received curative treatment, and 21 patients received palliative treatment. Cryoablation achieved 100% local control in pure ground-glass nodules (pGGNs), while local recurrence occurred in one part-solid and two solid nodules. Among 22 patients with sMPN, all the patients showed 100% LRFS and RFS, regardless of whether they received combined surgery and cryoablation or cryoablation alone. In 15 patients with SPLC, local control was 100%, but three developed recurrence or metastasis outside the ablation zone. The median PFS in the palliative group was 409 days. Pulmonary function did not show significant deterioration after cryoablation. Pneumothorax and hemoptysis were the most common adverse events (21.4% each), with a fatal complication rate of 0.9%.
conclusionCryoablation preserves pulmonary function and may benefit patients ineligible for surgery. It may serve as a treatment option for patients with unresectable pure ground-glass nodules or GGN-dominant MPN. Careful avoidance of vascular injury during the procedure is critical to minimizing the risk of potentially fatal complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.